Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system

References

• Silberstein SJL. Migraine. Lancet. 2004;363(9406):381–391. doi: 10.1016/S0140-6736(04)15440-8
   PubMed Web of Science ®Google Scholar
• Robbins MJJ. Diagnosis and management of headache: a review. JAMA. 2021;325(18):1874–1885. doi: 10.1001/jama.2021.1640
   PubMed Web of Science ®Google Scholar
• Dodick DJL. Migraine. Lancet. 2018;391(10127):1315–1330. doi: 10.1016/S0140-6736(18)30478-1
   PubMed Web of Science ®Google Scholar
• GJTAjomc P. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25:S23–S34. PMID: 30681821.
   PubMed Web of Science ®Google Scholar
• Zobdeh F, Ben Kraiem A, Attwood M, et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021;178(23):4588–4607. doi: 10.1111/bph.15657
   PubMed Web of Science ®Google Scholar
• Curto M, Capi M, Cipolla F, et al. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;21(7):755–759. doi: 10.1080/14656566.2020.1721462
   PubMed Web of Science ®Google Scholar
• LJRn E. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021;177(7):785–790. doi: 10.1016/j.neurol.2021.06.003
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338–350. doi: 10.1038/s41582-018-0003-1
   PubMed Web of Science ®Google Scholar
• Lipton R, Dodick D, Ailani J, et al. Effect of Ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898. doi: 10.1001/jama.2019.16711
   PubMed Web of Science ®Google Scholar
• Scott LJD. Correction to: ubrogepant: first approval. Erratum For: Drugs. 2020;80(5):523. doi: 10.1007/s40265-020-01292-1
   PubMed Web of Science ®Google Scholar
• Wu S, LJTIjon C. Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies. Int J Neurosci. 2022;26:1–7. doi: 10.1080/00207454.2022.2090351
   Google Scholar
• Yang Y, Chen M, Sun Y, et al. Safety and efficacy of Ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463–471. doi: 10.1007/s40263-020-00715-7
   PubMed Web of Science ®Google Scholar
• Hu Y, Bai Z, Tang Y, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J Diabetes Res. 2020;2020:3695101. doi: 10.1155/2020/3695101
   PubMed Web of Science ®Google Scholar
• Michel C, Scosyrev E, Petrin M, et al. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415–422. doi: 10.1007/s40261-017-0503-6
   PubMed Web of Science ®Google Scholar
• Zorych I, Madigan D, Ryan P, et al. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56. doi: 10.1177/0962280211403602
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Simonetta I. Molecular research on migraine: from pathogenesis to treatment. Int J Mol Sci. 2023;24(10):8681. doi: 10.3390/ijms24108681
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton R, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi: 10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Nedd M, Garland S, Falk N, et al. Ubrogepant: an oral Calcitonin Gene-Related Peptide (CGRP) receptor antagonist for abortive migraine treatment. Ann Pharmacother. 2022;56(3):346–351. doi: 10.1177/10600280211023810
   PubMed Web of Science ®Google Scholar
• Hutchinson S, Silberstein S, Blumenfeld A, et al. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021;41(9):979–990. doi: 10.1177/03331024211000311
   PubMed Web of Science ®Google Scholar
• Lipton RB, Singh RBH, Revicki DA, et al. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022;23(1):50. doi: 10.1186/s10194-022-01419-7
   PubMed Web of Science ®Google Scholar
• Navratilova E, Behravesh S, Oyarzo J, et al. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020;40(9):892–902. doi: 10.1177/0333102420938652
   PubMed Web of Science ®Google Scholar
• Battini V, Carnovale C, Clementi E, et al. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and drug administration adverse event reporting system. Expert Opin Drug Saf. 2023;12:1–8. doi: 10.1080/14740338.2023.2223958
   Google Scholar
• Voss T, Lipton R, Dodick D, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898. doi: 10.1177/0333102416653233
   PubMed Web of Science ®Google Scholar
• Do T, Guo S, MJTjoh A, et al. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37. doi: 10.1186/s10194-019-0974-3
   PubMedGoogle Scholar
• Ailani J, Lipton R, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141–152. doi: 10.1111/head.13682
   PubMed Web of Science ®Google Scholar
• Lipton R, Dodick D, Goadsby P, et al. Efficacy of Ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology. 2022;99(17):e1905–e1915. doi: 10.1212/WNL.0000000000201031
   PubMed Web of Science ®Google Scholar
• Chiang C, Arca K, Dunn R, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61(4):620–627. doi: 10.1111/head.14062
   PubMed Web of Science ®Google Scholar
• Goadsby P, Tepper S, Watkins P, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019;39(14):1753–1761. doi: 10.1177/0333102419869918
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton R, Ailani J, et al. Ubrogepant, an acute treatment for migraine, Improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. doi: 10.1111/head.13766
   PubMed Web of Science ®Google Scholar
• Hutchinson S, Dodick D, Treppendahl C, et al. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021;10(1):235–249. doi: 10.1007/s40120-021-00234-7
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld A, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–652. doi: 10.1111/head.14095
   PubMed Web of Science ®Google Scholar